✦ LIBER ✦

An Open-Label, Dose-Escalating Phase I Study of Elsamitrucin (SPI 28090) in Treatment of Malignant Solid Tumors in Dogs

✍ Scribed by S.C. Fiocchi; K.A. Selting; M.P. Rosenberg; P. Kolli; G. Lenaz; C. Henry

Book ID: 118095518
Publisher: John Wiley and Sons
Year: 2011
Tongue: English
Weight: 112 KB
Volume: 25
Category: Article
ISSN: 0891-6640
DOI: 10.1111/j.1939-1676.2011.0752.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Pharmacokinetics and Tolerability of Van

Pharmacokinetics and Tolerability of Vandetanib in Chinese Patients With Solid, Malignant Tumors: An Open-Label, Phase I, Rising Multiple-Dose Study

✍ Li Zhang; Su Li; Yang Zhang; Jing Zhan; Ben-Yan Zou; Robert Smith; Paul D. Marti 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 712 KB

An open-label, dose-escalation study of

An open-label, dose-escalation study of ZD0473 combined with paclitaxel in refractory solid malignancies

✍ Gatzemeier, U; Kaye, S.B; Groth, G; Anthoney, D.A; Cosaert, J 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 228 KB

Phase I dose-escalating study of ES-285

Phase I dose-escalating study of ES-285 given as a three-hour intravenous infusion every three weeks in patients with advanced malignant solid tumors

✍ C. Massard, R. Salazar, J. P. Armand, M. Majem, E. Deutsch, M. García, A. Oaknin 📂 Article 📅 2012 🏛 Springer US 🌐 English ⚖ 591 KB

Phase I, Dose-Escalation Study of BKM120

Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors

✍ Bendell, J. C.; Rodon, J.; Burris, H. A.; de Jonge, M.; Verweij, J.; Birle, D.; 📂 Article 📅 2012 🏛 American Society of Clinical Oncology 🌐 English ⚖ 196 KB

Phase I dose escalation study of weekly

Phase I dose escalation study of weekly ixabepilone, an epothilone analog, in patients with advanced solid tumors who have failed standard therapy

✍ Ahmad Awada; Martine J. Piccart; Suzanne F. Jones; Ronald A. Peck; Thierry Gil; 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 358 KB

A Phase I Dose-Escalation Study of Regor

A Phase I Dose-Escalation Study of Regorafenib (BAY 73-4506), an Inhibitor of Oncogenic, Angiogenic, and Stromal Kinases, in Patients with Advanced Solid Tumors

✍ Mross, K.; Frost, A.; Steinbild, S.; Hedbom, S.; Buchert, M.; Fasol, U.; Unger, 📂 Article 📅 2012 🏛 American Association for Cancer Research 🌐 English ⚖ 392 KB